Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia

Ayalew Tefferi, Ruben A. Mesa, Leigh A. Gray, David P. Steensma, John K Camoriano, Michelle A. Elliott, Animesh D Pardanani, Stephen Maxted Ansell, Timothy G. Call, Gerardo Colon-Otero, Georgene Schroeder, Curtis A. Hanson, Gordon W. Dewald, Scott H Kaufmann

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

In a phase 2 study, 23 patients with myelofibrosis with myeloid metaplasia were treated with imatinib mesylate at a constant dose of 400 mg/d. Treatment was held in 16 patients (70%), after 1 to 12 weeks, because of side effects (neutropenia, 6 patients; musculoskeletal pain, 5 patients; thrombocytosis, 4 patients; edema, 3 patients; diarrhea and hyperbilirubinemia, 1 patient). Including patients in whom retreatment at a reduced dose was possible, 11 patients (48%) were able to continue treatment beyond 3 months. None of the patients experienced a response in anemia, and only 2 had partial responses in splenomegaly. A greater than 50% increase in platelet count was documented in 11 (48%) patients, but not in those with baseline platelet counts of less than 100 × 109/L. In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit.

Original languageEnglish (US)
Pages (from-to)3854-3856
Number of pages3
JournalBlood
Volume99
Issue number10
DOIs
StatePublished - May 15 2002

Fingerprint

Primary Myelofibrosis
Platelets
Platelet Count
Imatinib Mesylate
Gilbert Disease
Thrombocytosis
Musculoskeletal Pain
Retreatment
Splenomegaly
Neutropenia
Anemia
Diarrhea
Edema

ASJC Scopus subject areas

  • Hematology

Cite this

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. / Tefferi, Ayalew; Mesa, Ruben A.; Gray, Leigh A.; Steensma, David P.; Camoriano, John K; Elliott, Michelle A.; Pardanani, Animesh D; Ansell, Stephen Maxted; Call, Timothy G.; Colon-Otero, Gerardo; Schroeder, Georgene; Hanson, Curtis A.; Dewald, Gordon W.; Kaufmann, Scott H.

In: Blood, Vol. 99, No. 10, 15.05.2002, p. 3854-3856.

Research output: Contribution to journalArticle

Tefferi, A, Mesa, RA, Gray, LA, Steensma, DP, Camoriano, JK, Elliott, MA, Pardanani, AD, Ansell, SM, Call, TG, Colon-Otero, G, Schroeder, G, Hanson, CA, Dewald, GW & Kaufmann, SH 2002, 'Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia', Blood, vol. 99, no. 10, pp. 3854-3856. https://doi.org/10.1182/blood-2001-12-0154
Tefferi, Ayalew ; Mesa, Ruben A. ; Gray, Leigh A. ; Steensma, David P. ; Camoriano, John K ; Elliott, Michelle A. ; Pardanani, Animesh D ; Ansell, Stephen Maxted ; Call, Timothy G. ; Colon-Otero, Gerardo ; Schroeder, Georgene ; Hanson, Curtis A. ; Dewald, Gordon W. ; Kaufmann, Scott H. / Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. In: Blood. 2002 ; Vol. 99, No. 10. pp. 3854-3856.
@article{1d0d013447934daab2ebb5821585cbe5,
title = "Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia",
abstract = "In a phase 2 study, 23 patients with myelofibrosis with myeloid metaplasia were treated with imatinib mesylate at a constant dose of 400 mg/d. Treatment was held in 16 patients (70{\%}), after 1 to 12 weeks, because of side effects (neutropenia, 6 patients; musculoskeletal pain, 5 patients; thrombocytosis, 4 patients; edema, 3 patients; diarrhea and hyperbilirubinemia, 1 patient). Including patients in whom retreatment at a reduced dose was possible, 11 patients (48{\%}) were able to continue treatment beyond 3 months. None of the patients experienced a response in anemia, and only 2 had partial responses in splenomegaly. A greater than 50{\%} increase in platelet count was documented in 11 (48{\%}) patients, but not in those with baseline platelet counts of less than 100 × 109/L. In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit.",
author = "Ayalew Tefferi and Mesa, {Ruben A.} and Gray, {Leigh A.} and Steensma, {David P.} and Camoriano, {John K} and Elliott, {Michelle A.} and Pardanani, {Animesh D} and Ansell, {Stephen Maxted} and Call, {Timothy G.} and Gerardo Colon-Otero and Georgene Schroeder and Hanson, {Curtis A.} and Dewald, {Gordon W.} and Kaufmann, {Scott H}",
year = "2002",
month = "5",
day = "15",
doi = "10.1182/blood-2001-12-0154",
language = "English (US)",
volume = "99",
pages = "3854--3856",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia

AU - Tefferi, Ayalew

AU - Mesa, Ruben A.

AU - Gray, Leigh A.

AU - Steensma, David P.

AU - Camoriano, John K

AU - Elliott, Michelle A.

AU - Pardanani, Animesh D

AU - Ansell, Stephen Maxted

AU - Call, Timothy G.

AU - Colon-Otero, Gerardo

AU - Schroeder, Georgene

AU - Hanson, Curtis A.

AU - Dewald, Gordon W.

AU - Kaufmann, Scott H

PY - 2002/5/15

Y1 - 2002/5/15

N2 - In a phase 2 study, 23 patients with myelofibrosis with myeloid metaplasia were treated with imatinib mesylate at a constant dose of 400 mg/d. Treatment was held in 16 patients (70%), after 1 to 12 weeks, because of side effects (neutropenia, 6 patients; musculoskeletal pain, 5 patients; thrombocytosis, 4 patients; edema, 3 patients; diarrhea and hyperbilirubinemia, 1 patient). Including patients in whom retreatment at a reduced dose was possible, 11 patients (48%) were able to continue treatment beyond 3 months. None of the patients experienced a response in anemia, and only 2 had partial responses in splenomegaly. A greater than 50% increase in platelet count was documented in 11 (48%) patients, but not in those with baseline platelet counts of less than 100 × 109/L. In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit.

AB - In a phase 2 study, 23 patients with myelofibrosis with myeloid metaplasia were treated with imatinib mesylate at a constant dose of 400 mg/d. Treatment was held in 16 patients (70%), after 1 to 12 weeks, because of side effects (neutropenia, 6 patients; musculoskeletal pain, 5 patients; thrombocytosis, 4 patients; edema, 3 patients; diarrhea and hyperbilirubinemia, 1 patient). Including patients in whom retreatment at a reduced dose was possible, 11 patients (48%) were able to continue treatment beyond 3 months. None of the patients experienced a response in anemia, and only 2 had partial responses in splenomegaly. A greater than 50% increase in platelet count was documented in 11 (48%) patients, but not in those with baseline platelet counts of less than 100 × 109/L. In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit.

UR - http://www.scopus.com/inward/record.url?scp=0037093060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037093060&partnerID=8YFLogxK

U2 - 10.1182/blood-2001-12-0154

DO - 10.1182/blood-2001-12-0154

M3 - Article

C2 - 11986248

AN - SCOPUS:0037093060

VL - 99

SP - 3854

EP - 3856

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -